Navigation Links
MultiVu Video Feed: POSITIVE PHASE 3 TRIAL DATA FOR INVESTIGATIONAL NEW MIGRAINE TREATMENT PRESENTED IN LATE-BREAKING SESSION AT 14th ANNUAL INTERNATIONAL HEADACHE SOCIETY CONGRESS
Date:9/10/2009

LEVADEX Analysis Shows Potential to Treat a Broad Spectrum of Migraine ***UPDATED SATELLITE COORDINATES***

Migraine is a common, debilitating neurological disorder that affects approximately 30 million people in the United States, according to the National Headache Foundation. Limitations of oral triptans, the class of prescription drugs widely used for migraines, include slow onset of significant pain relief between 45 and 90 minutes, substantial variability in patient response and side effects such as heightened blood pressure.

MAP Pharmaceuticals, Inc. will present analysis of data from the efficacy portion of the first Phase 3 trial of LEVADEX(TM) at the 14th Congress of the International Headache Society. Data from this Phase 3 trial show the potential of LEVADEX to be effective in treating acute migraine as well as a broad spectrum of migraine, including migraine subpopulations that are often resistant to current therapies, migraine with moderate and severe pain, migraine with nausea and vomiting, and migraine with and without aura. LEVADEX is an orally inhaled migraine therapy that patients administer themselves using the company's proprietary TEMPO(R) inhaler.

    SATELLITE FEED:
    Thursday, September 10th, 2009
    2:00 PM - 2:15 PM ET
    Galaxy 19
    C-Band
    Transponder 10
    Downlink Freq. 3900 Horizontal

NEWS: New Data Presented at the International Headache Society's Annual Congress Suggests New, Investigational Migraine Treatment Could Help Provide Relief for 30 Million Sufferers in the U.S.

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/40023/consumer.html


    SOUNDBITES:
    * Dr. Stephen Silberstein, Director of the Headache Center, Jefferson
      University Hospitals
    * Migraine patient

    B-ROLL INCLUDES:
    * Dr/Patient footage
    * MAP corporate headquarters - exteriors and lab footage
    * manufacturing footage
    * product shots

VIDEO PROVIDED BY: MAP Pharmaceuticals, Inc.

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE MAP Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy
2. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
3. Video: MADIT-CRT Trial Results Provide Clinical Evidence That Cardiac Resynchronization Therapy Significantly Slows Heart Failure Progression
4. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
5. Medigus and Tower Semiconductor Announce Worlds Smallest Medical Video Camera Based on Advanced CMOS Image Sensor
6. Video: New Dove(R) Body Washes with NutriumMoisture(TM) Restore Skins Natural Moisture
7. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
8. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
9. Video: UCB Launches Vimpat(R) in the U.S. for Add-On Treatment of Epilepsy in Adults
10. Video: Partnership Unites UCB with Consumer Product Innovator OXO(R)
11. VIDEO from Medialink and the Epilepsy Foundation: New Study Suggests Different Versions of the Same Epilepsy Medication Can Be Harmful
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences ... Company specializing in the development of cannabinoid-based drugs, ... a company overview at three upcoming scientific and ... Annual LD Micro Invitational: ... Date:                     ...
(Date:5/26/2017)... 2017  In response to the opioid epidemic in ... is working with Pfizer to make up to 1 ... to community health centers, free and charitable clinics, public ... "Pfizer has a long-standing commitment to improving health ... safety through educational activities," said Caroline Roan , ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
Breaking Medicine Technology:
(Date:6/20/2017)... MA (PRWEB) , ... June 20, 2017 , ... Kenneth ... International AIDS Society (JIAS). , Dr. Mayer, who joined the JIAS Editorial Board ... is the founding Medical Research Director of Fenway Health and Co-Chair of ...
(Date:6/20/2017)... (PRWEB) , ... June 20, 2017 , ... HOUSTON – ... new website and a host of new options for today’s modern senior. Brazos ... maintain the active, independent lifestyle they love while offering them the services to support ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... content solutions for the enterprise, is proud to announce Touchpoints integrations. ... ticketing systems, company websites, and more to provide a seamless customer experience. , ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... in Cincinnati, OH for leading-edge care, whether or not they have a ... Using the BIOLASE WaterLase® iPlus™ laser, she targets bacteria and damaged tissue without ...
(Date:6/20/2017)... ... ... With certifications and experience that puts them at the top of the ... are currently accepting new patients at their practice for these custom clear aligners. These ... is why they offer the latest in modern dental techniques to ensure that all ...
Breaking Medicine News(10 mins):